痰热清治疗小儿支气管肺炎临床效果研究

Clinical effects of Tanreqing on pediatric bronchial pneumonia

目的探讨痰热清治疗小儿支气管肺炎临床效果及安全性。方法将十堰市妇幼保健院收治的54例支气管肺炎患儿随机分为研究组和对照组各27例,对照组采用抗生素联合抗病毒药物、对症治疗;研究组在对照组基础上加用痰热清静脉滴注。观察临床症状消失时间、不良反应及总有效率。结果研究组退热时间、咳嗽消失时间、咽痛消失时间及治愈时间均低于对照组,差异均具有统计学意义(t值分别为7.53、5.94、3.58、5.22,均P<0.05)。研究组总有效率(88.89%)明显高于对照组(70.37%),差异显著(x^2=8.21,P<0.05)。两组不良反应发生率对比,无统计学差异(X^2=0.09,P>0.05)。结论痰热清治疗小儿支气管肺炎疗效优越且未增加不良反应,可迅速控制病情,降低体温,预防惊厥发生,特别适用于基层医院或门诊,对病原菌无法辨别的患儿,值得临床推广。

Objective To investigate the clinical effect and safety of Tanreqing on treatment of pediatric bronchial pneumonia. Methods Fifty-four cases of bronchial pneumonia were randomly divided into research group and control group with 27 cases in each. The control group adopted combined antiviral drugs and antibiotics symptomatic treatment,while the research group was given Tanreqing intravenous drip based on the treatment for the control group. Clinical symptoms disappearance time, adverse reactions and total effective rate were observed. Results The disappearance time for pyretolysis, cough, sore throat and fever, and cure time in the research group were shorter than the control group, and the differences were significant （t value was 7. 53, 5. 94, 3. 58 and 5. 22, respectively, all P〈0. 05）. The total effective rate of the research group was significantly higher than the control group （88. 89% vs 70. 37%） with significant difference （χ2 =8. 21,P 〈0. 05）. There was no difference in the incidence of adverse reactions between two groups （χ2 =0. 09,P 〉0. 05）. Conclusion Tanreqing for treatment of pediatric bronchial pneumonia has superior efficacy without increasing adverse reactions. It can control disease condition, lower body temperature and prevent the incidence of eclampsia, which is suitable for grass-roots hospitals or clinics. It is worthy of clinical promotion for children patients infected with undistinguished pathogens.